Heron Therapeutics | HRTX - Ebitda



金融业
股票价格
USD
资产
USD 252.26M
现金及等价物
USD 20.72M
销售成本
USD 11.12M
流动资产
USD 229.85M
流动负债
USD 92.15M
债务
USD 149.65M
股息收益率
0
EBIT
USD 38K
EBITDA
USD -3.88M
员工
126
EPS每股收益
USD -0.02
股本和储备
USD 6.91M
销售毛利
USD 29.47M
债务利息支出
USD 600K
利息收入
USD 433K
贷款资金
USD 140.64M
市值
USD 49.9M
净收入
USD -2.95M
营业费用
USD 40.55M
营业利润
USD 38K
普通股股本
USD 188.31M
税前利润
USD -2.95M
销售收入
USD 40.59M
销售和管理费用
USD 23.74M
股票
USD 54.57M
贸易债权人
USD 11.64M
应收帐款人
USD 89.59M


Ebitda 更改 日
ALKERMES USD 139.22M 58.96M 2026-06
Alnylam Pharmaceuticals USD 245.34M 59.15M 2026-06
Amarin USD 12.54M 28.57M 2025-06
ANI Pharmaceuticals USD 71.6M 6.69M 2026-06
Anika Therapeutics USD 4.54M 3.67M 2025-12
Arrowhead Research USD -147.68M 40.33M 2026-06
Eisai JPY 34.15B 34.48B 2026-06
GlaxoSmithKline GBP 3.51B 734M 2026-06
Heron Therapeutics USD -3.88M 5.63M 2024-09
Insmed USD -148.3M 165.88M 2026-03
Ligand Pharmaceuticals USD -14.3M 81.08M 2026-03
Merck USD -1.54B 7.84B 2026-03
Nektar Therapeutics USD -38.9M 7.09M 2026-03
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Omeros USD -47.96M 7.39M 2023-09
Pacira USD 48.67M 8.43M 2026-06
Regeneron Pharmaceuticals USD 1.66B 695.2M 2026-06
Roche Holding CHF 13.43B 744M 2026-06
Ultragenyx Pharmaceutical USD -155M 55.57M 2026-03
Veracyte USD 43.96M 1.16M 2026-06
Vertex Pharmaceuticals USD 1.33B 130.5M 2026-06